AU4418400A - Treatment, imaging and diagnosis of disease using an agent which binds alfa5-integrin - Google Patents
Treatment, imaging and diagnosis of disease using an agent which binds alfa5-integrinInfo
- Publication number
- AU4418400A AU4418400A AU44184/00A AU4418400A AU4418400A AU 4418400 A AU4418400 A AU 4418400A AU 44184/00 A AU44184/00 A AU 44184/00A AU 4418400 A AU4418400 A AU 4418400A AU 4418400 A AU4418400 A AU 4418400A
- Authority
- AU
- Australia
- Prior art keywords
- alfa5
- integrin
- binds
- diagnosis
- imaging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Gynecology & Obstetrics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9909392.4A GB9909392D0 (en) | 1999-04-24 | 1999-04-24 | Treatment, imaging and diagnosis of disease |
GB9909392 | 1999-04-24 | ||
PCT/GB2000/001446 WO2000064480A1 (en) | 1999-04-24 | 2000-04-13 | Treatment, imaging and diagnosis of disease using an agent which binds alfa5-integrin |
Publications (1)
Publication Number | Publication Date |
---|---|
AU4418400A true AU4418400A (en) | 2000-11-10 |
Family
ID=10852148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU44184/00A Abandoned AU4418400A (en) | 1999-04-24 | 2000-04-13 | Treatment, imaging and diagnosis of disease using an agent which binds alfa5-integrin |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU4418400A (en) |
GB (1) | GB9909392D0 (en) |
WO (1) | WO2000064480A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1539247A4 (en) * | 2002-07-16 | 2007-08-29 | Univ New Jersey Med | Alpha 5 beta 1 and its ability to regulate the cell survival pathway |
WO2004069281A1 (en) * | 2003-01-30 | 2004-08-19 | The General Hospital Corporation | Bifunctional molecules comprising at least one integrin-binding and their use in imaging and therapy of angiogenesis and related disorders |
CA2591148A1 (en) * | 2004-12-09 | 2006-06-15 | Centocor, Inc. | Anti-integrin immunoconjugates, methods and uses |
NZ615012A (en) | 2006-03-21 | 2015-11-27 | Genentech Inc | Combinatorial therapy involving alpha5beta1 antagonists |
US20080038190A1 (en) * | 2006-08-11 | 2008-02-14 | Simpson Thomas J | Composition apparatus and method for use in imaging |
AR066170A1 (en) | 2007-09-26 | 2009-07-29 | Genentech Inc | ANTI INTEGRINA ALFA 5 BETA 1 |
CA2753988C (en) | 2009-03-25 | 2017-04-25 | Genentech, Inc. | Novel anti-.alpha.5.beta. integrin antibodies and uses thereof |
AU2016340763B2 (en) | 2015-10-23 | 2021-04-22 | Jai Prakash | Integrin binding peptides and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2861692A (en) * | 1991-10-18 | 1993-05-21 | Beth Israel Hospital Association, The | Vascular permeability factor targeted compounds |
US5981478A (en) * | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
PT1075277E (en) * | 1998-05-08 | 2009-05-08 | Univ California | Methods for detecting and inhibiting angiogenesis |
-
1999
- 1999-04-24 GB GBGB9909392.4A patent/GB9909392D0/en not_active Ceased
-
2000
- 2000-04-13 AU AU44184/00A patent/AU4418400A/en not_active Abandoned
- 2000-04-13 WO PCT/GB2000/001446 patent/WO2000064480A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2000064480A1 (en) | 2000-11-02 |
GB9909392D0 (en) | 1999-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001262943A1 (en) | Methods for drug discovery, disease treatment, and diagnosis using metabolomics | |
AU2002323258A1 (en) | Diagnosis and treatment of vascular disease | |
AU2002362608A1 (en) | Cardiac catheter imaging system | |
AU5902500A (en) | Destruction pulse ultrasound contrast agent imaging | |
AU2002367535A1 (en) | Diagnosis and treatment of vascular disease | |
AU2001235018A1 (en) | Medical diagnostic ultrasound system using contrast pulse sequence imaging | |
AU2001227815A1 (en) | Chemically specific imaging of tissue | |
AU2001275177A1 (en) | Cardiac disease treatment and device | |
AU2001253565A1 (en) | Cardiac disease treatment and device | |
AU2001275176A1 (en) | Cardiac disease treatment and device | |
AU2001281369A1 (en) | Cardiac disease treatment and device | |
GB9909966D0 (en) | Analysis of fundus images | |
AU2003223172A1 (en) | Use of the axl receptor for diagnosis and treatment of renal disease | |
AU2003286726A1 (en) | Methods for drug discovery, disease treatment, and diagnosis using metabolomics | |
AU2003291536A1 (en) | Method for the diagnosis and treatment of vascular disease | |
AU2002326813A1 (en) | Diagnosis and treatment of vascular disease | |
AU6425800A (en) | Agents for the diagnosis, prognosis and treatment of malignant diseases | |
AU4418400A (en) | Treatment, imaging and diagnosis of disease using an agent which binds alfa5-integrin | |
AU2003210266A1 (en) | Treatment, diagnosis and imaging of disease | |
AU2002341880A1 (en) | Diagnosis and treatment of vascular disease | |
AU4204700A (en) | Compounds and methods for the diagnosis and treatment of (b. microti) infection | |
AU5550800A (en) | Diagnosis and treatment of alzheimer's disease | |
AU2002341604A1 (en) | Diagnosis and treatment of vascular disease | |
AU4654500A (en) | Prevention, diagnosis and treatment of lyme disease | |
AU1820499A (en) | Compounds and methods for the diagnosis and treatment of (b. microti) infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |